Tendon and motor phenotypes in the Crtap-/- mouse model of recessive Osteogenesis Imperfecta

  1. Matthew William Grol  Is a corresponding author
  2. Nele A Haelterman
  3. Joohyun Lim
  4. Elda M Munivez
  5. Marilyn Archer
  6. David M Hudson
  7. Sara F Tufa
  8. Douglas R Keene
  9. Kevin Lei
  10. Dongsu Park
  11. Cole D Kuzawa
  12. Catherine G Ambrose
  13. David R Eyre
  14. Brendan H Lee  Is a corresponding author
  1. University of Western Ontario, Canada
  2. Baylor College of Medicine, United States
  3. University of Washington, United States
  4. Shriners Hospital for Children, United States
  5. The University of Texas Health Sciences Center at Houston, United States

Abstract

Osteogenesis imperfecta (OI) is characterized by short stature, skeletal deformities, low bone mass, and motor deficits. A subset of OI patients also present with joint hypermobility; however, the role of tendon dysfunction in OI pathogenesis is largely unknown. Using the Crtap-/- mouse model of severe, recessive OI, we found that mutant Achilles and patellar tendons were thinner and weaker with increased collagen cross-links and reduced collagen fibril size at 1- and 4-months compared to wildtype. Patellar tendons from Crtap-/- mice also had altered numbers of CD146+CD200+ and CD146-CD200+ progenitor-like cells at skeletal maturity. RNA-seq analysis of Achilles and patellar tendons from 1-month Crtap-/- mice revealed dysregulation in matrix and tendon marker gene expression concomitant with predicted alterations in TGF-b, inflammatory, and metabolic signaling. At 4-months, Crtap-/- mice showed increased aSMA, MMP2, and phospho-NFkB in the patellar tendon consistent with excess matrix remodeling and tissue inflammation. Finally, a series of behavioral tests showed severe motor impairments and reduced grip strength in 4-month Crtap-/- mice – a phenotype that correlates with the tendon pathology.

Data availability

All data generated or analyzed during this study are included in the manuscript and supporting files. Source data files have been provided for Figure 6 that include full lists of differentially expressed genes resulting from RNA-seq analysis of Achilles and patellar tendons from 1- month wild-type and Crtap-/- mice. For each, a list of predicted upstream regulators identified using Ingenuity Pathway Analysis is also included.

Article and author information

Author details

  1. Matthew William Grol

    Physiology and Pharmacology, University of Western Ontario, London, Canada
    For correspondence
    mgrol2@uwo.ca
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-6514-9066
  2. Nele A Haelterman

    Baylor College of Medicine, Houston, United States
    Competing interests
    The authors declare that no competing interests exist.
  3. Joohyun Lim

    Baylor College of Medicine, Houston, United States
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-9670-806X
  4. Elda M Munivez

    Baylor College of Medicine, Houston, United States
    Competing interests
    The authors declare that no competing interests exist.
  5. Marilyn Archer

    Orthopaedics and Sports Medicine, University of Washington, Seattle, United States
    Competing interests
    The authors declare that no competing interests exist.
  6. David M Hudson

    Orthopaedics and Sports Medicine, University of Washington, Seattle, United States
    Competing interests
    The authors declare that no competing interests exist.
  7. Sara F Tufa

    Shriners Hospital for Children, Portland, United States
    Competing interests
    The authors declare that no competing interests exist.
  8. Douglas R Keene

    Shriners Hospital for Children, Portland, United States
    Competing interests
    The authors declare that no competing interests exist.
  9. Kevin Lei

    Baylor College of Medicine, Houston, United States
    Competing interests
    The authors declare that no competing interests exist.
  10. Dongsu Park

    Baylor College of Medicine, Houston, United States
    Competing interests
    The authors declare that no competing interests exist.
  11. Cole D Kuzawa

    Orthopaedic Surgery, The University of Texas Health Sciences Center at Houston, Houston, United States
    Competing interests
    The authors declare that no competing interests exist.
  12. Catherine G Ambrose

    Orthopaedic Surgery, The University of Texas Health Sciences Center at Houston, Houston, United States
    Competing interests
    The authors declare that no competing interests exist.
  13. David R Eyre

    Orthopaedics and Sports Medicine, University of Washington, Seattle, United States
    Competing interests
    The authors declare that no competing interests exist.
  14. Brendan H Lee

    Baylor College of Medicine, Houston, United States
    For correspondence
    blee@bcm.edu
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-8573-4211

Funding

Eunice Kennedy Shriver National Institute of Child Health and Human Development (HD024064)

  • Brendan H Lee

Rolanette and Berdon Lawrence Bone Disease Program of Texas

  • Brendan H Lee

BCM Center for Skeletal Medicine and Biology

  • Brendan H Lee

Pamela and David Ott Center for Heritable Disorders of Connective Tissue

  • Brendan H Lee

National Institute of Arthritis and Musculoskeletal and Skin Diseases (AR373318)

  • David R Eyre

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Reviewing Editor

  1. Cheryl Ackert-Bicknell, University of Colorado, United States

Ethics

Animal experimentation: This study was performed in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. All of the animals were handled according to approved Institutional Animal Care and Use Committee (IACUC) protocols (#AN-1506) at Baylor College of Medicine.

Version history

  1. Received: September 25, 2020
  2. Accepted: May 24, 2021
  3. Accepted Manuscript published: May 26, 2021 (version 1)
  4. Version of Record published: June 8, 2021 (version 2)

Copyright

© 2021, Grol et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 1,202
    views
  • 156
    downloads
  • 11
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Matthew William Grol
  2. Nele A Haelterman
  3. Joohyun Lim
  4. Elda M Munivez
  5. Marilyn Archer
  6. David M Hudson
  7. Sara F Tufa
  8. Douglas R Keene
  9. Kevin Lei
  10. Dongsu Park
  11. Cole D Kuzawa
  12. Catherine G Ambrose
  13. David R Eyre
  14. Brendan H Lee
(2021)
Tendon and motor phenotypes in the Crtap-/- mouse model of recessive Osteogenesis Imperfecta
eLife 10:e63488.
https://doi.org/10.7554/eLife.63488

Share this article

https://doi.org/10.7554/eLife.63488

Further reading

    1. Genetics and Genomics
    2. Neuroscience
    Bohan Zhu, Richard I Ainsworth ... Javier González-Maeso
    Research Article

    Genome-wide association studies have revealed >270 loci associated with schizophrenia risk, yet these genetic factors do not seem to be sufficient to fully explain the molecular determinants behind this psychiatric condition. Epigenetic marks such as post-translational histone modifications remain largely plastic during development and adulthood, allowing a dynamic impact of environmental factors, including antipsychotic medications, on access to genes and regulatory elements. However, few studies so far have profiled cell-specific genome-wide histone modifications in postmortem brain samples from schizophrenia subjects, or the effect of antipsychotic treatment on such epigenetic marks. Here, we conducted ChIP-seq analyses focusing on histone marks indicative of active enhancers (H3K27ac) and active promoters (H3K4me3), alongside RNA-seq, using frontal cortex samples from antipsychotic-free (AF) and antipsychotic-treated (AT) individuals with schizophrenia, as well as individually matched controls (n=58). Schizophrenia subjects exhibited thousands of neuronal and non-neuronal epigenetic differences at regions that included several susceptibility genetic loci, such as NRG1, DISC1, and DRD3. By analyzing the AF and AT cohorts separately, we identified schizophrenia-associated alterations in specific transcription factors, their regulatees, and epigenomic and transcriptomic features that were reversed by antipsychotic treatment; as well as those that represented a consequence of antipsychotic medication rather than a hallmark of schizophrenia in postmortem human brain samples. Notably, we also found that the effect of age on epigenomic landscapes was more pronounced in frontal cortex of AT-schizophrenics, as compared to AF-schizophrenics and controls. Together, these data provide important evidence of epigenetic alterations in the frontal cortex of individuals with schizophrenia, and remark for the first time on the impact of age and antipsychotic treatment on chromatin organization.

    1. Cancer Biology
    2. Genetics and Genomics
    Kevin Nuno, Armon Azizi ... Ravindra Majeti
    Research Article

    Relapse of acute myeloid leukemia (AML) is highly aggressive and often treatment refractory. We analyzed previously published AML relapse cohorts and found that 40% of relapses occur without changes in driver mutations, suggesting that non-genetic mechanisms drive relapse in a large proportion of cases. We therefore characterized epigenetic patterns of AML relapse using 26 matched diagnosis-relapse samples with ATAC-seq. This analysis identified a relapse-specific chromatin accessibility signature for mutationally stable AML, suggesting that AML undergoes epigenetic evolution at relapse independent of mutational changes. Analysis of leukemia stem cell (LSC) chromatin changes at relapse indicated that this leukemic compartment underwent significantly less epigenetic evolution than non-LSCs, while epigenetic changes in non-LSCs reflected overall evolution of the bulk leukemia. Finally, we used single-cell ATAC-seq paired with mitochondrial sequencing (mtscATAC) to map clones from diagnosis into relapse along with their epigenetic features. We found that distinct mitochondrially-defined clones exhibit more similar chromatin accessibility at relapse relative to diagnosis, demonstrating convergent epigenetic evolution in relapsed AML. These results demonstrate that epigenetic evolution is a feature of relapsed AML and that convergent epigenetic evolution can occur following treatment with induction chemotherapy.